National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
302 articles with National Institute of Allergy & Infectious Diseases (NIAID)
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
Study on ChromaDex’s NR ingredient to be conducted at NIH-NIAID’s Rocky Mountain Labs, one of the few Biosafety Level 4 labs in the U.S.
Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
BiondVax Pharmaceuticals Ltd. announced the completion of the clinical study report of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
Meabco Awarded a $5.9 Million US Government Contract to Advance its BP-C2 Compound as a Medical Countermeasure for Cutaneous Radiation Injuries
Award from the National Institute of Allergy and Infectious Diseases (NIAID) Radiation and Nuclear Countermeasures Program
Dr. Anthony Fauci, Dr. Moncef Slaoui and Top COVID-19 Thought Leaders Take Stage During BIO Digital Week
Convening national experts at the epicenter of vaccine development for COVID-19 while presenting critical conversations on the state of the biopharma industry amid the pandemic
Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research
Adjuvance Technologies announced today that it has been awarded supplemental contract funding from The National Institute of Allergy and Infectious Diseases (NIAID). The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health). TQL1055 is Adjuvance’s novel Saponin vaccine adjuvant. The total funding in this contract is $1.47million. “
In an interview with National Geographic, Fauci once again sided with the evidence that indicates the virus is a species jumper and originated in the animal kingdom.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
Integral Molecular Receives NIAID Award to Combat COVID-19
The National Institute of Allergy and Infectious Diseases has awarded Integral Molecular $1 million to enable the application of Integral Molecular's technology platforms to aid in the discovery of vaccines and therapeutics to combat COVID-19.
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
BioCryst Pharmaceuticals, Inc. announced that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19.
Novel Coronavirus Can Survive in Aerosol Form and on Hard Surfaces for Hours to Days, Study Reveals
3/18/2020As the world shifts toward a concept of social distancing as part of an attempt to protect against the novel coronavirus, new research is showing the virus that causes COVID-19 is quite stable on hard surfaces, and even in the air.
OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2
OyaGen, Inc. announced today new unpublished results from collaborative research with the National Institute of Allergy and Infectious Diseases' Integrated Research Facility at Fort Detrick, MD
Clinical Catch-Up: February 3-7, 2020
2/10/2020Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
HIV Vaccine Trial HVTN 702 Stopped Early for Non-Efficacy; Other Vaccine Trials Not Affected; AVAC Calls for Ongoing Support to Vaccine Research
NEW YORK , Feb. 3, 2020 /PRNewswire/ -- Today the US National Institute of Allergy and Infectious Diseases (NIAID) announced that HVTN 702, a large-scale HIV vaccine efficacy trial of a canary pox-based vaccine candidate, has been stopped vaccinations because the vaccine does not prevent HIV.